Jump to content

Cetirizine

From Pharmacopedia
Revision as of 10:43, 23 May 2026 by MDElliottMD (talk | contribs) (home-claude category backfill (parser-claude gap closure))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Common uses
Allergic rhinitis0, Chronic idiopathic urticaria0, Allergic conjunctivitis0
Pharmacy
Starting dose
10 mg PO once daily (5 mg in older adults or if sedation occurs)
Preparations
5 mg, 10 mg tablets; 5 mg, 10 mg chewables; 1 mg/mL oral syrup; OTC
US FDA Max
10 mg/d (adults)
Pharmacology
Routes
Oral
Onset
30-60 minutes
Duration
24 hours
Half-life
8-10 hours (longer in elderly and renal impairment)[1]
Bioavailability
High (oral); not significantly affected by food[1]
Pregnancy
Generally considered safe; widely used. Levocetirizine (the R-enantiomer) is an alternative with similar safety.[citation needed]
Legal status
OTC in US
Purported mechanism
Cetirizine is a selective peripheral H1 receptor antagonist; as a carboxylated zwitterion at physiologic pH it crosses the blood-brain barrier far less than first-generation antihistamines, producing materially less sedation while retaining peripheral antihistaminic activity.0 Minimal CYP metabolism; mostly renally cleared unchanged. Cetirizine is the active racemate; levocetirizine is the active R-enantiomer marketed separately[1].

References

  1. 1.0 1.1 1.2 FDA Prescribing Information, Zyrtec (cetirizine HCl), Johnson & Johnson Consumer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019835s062lbl.pdf